Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet antiaggregate activity.

A Ordinas1

  • 1Hemotherapy and Hemostasic Service, Hospital Clinic i, Provincial, University of Barcelona, Spain.

American Heart Journal
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

A deleterious effect of aspirin on the antithrombotic properties of endothelial cells is not observed with platelets previously exposed to aspirin: studies in a flow system.

Platelets·2010
Same author

Effects of aspirin and indomethacin separately in red blood cells and platelets. Modulation of the adhesive and cohesive functions of platelets under flow conditions.

Platelets·2010
Same author

Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin.

European journal of clinical investigation·2006
Same author

1-Deamino (8-D-arginine) vasopressin infusion partially corrects platelet deposition on subendothelium in Bernard-Soulier syndrome: the role of factor VIII.

Platelets·2006
Same author

Frozen extracellular matrix preserves its thrombogenicity after thawing, while Matrigel induces a poor platelet response.

Platelets·2006
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Nicardipine treatment improved platelet aggregation in migraine sufferers, suggesting potential therapeutic effects on platelet function during migraine attacks. This finding offers new insights into migraine pathophysiology and treatment strategies.

Area of Science:

  • Cardiovascular Pharmacology
  • Neuroscience
  • Hematology

Background:

  • Platelet aggregation is crucial for hemostasis and thrombosis.
  • Altered platelet function, including hyperaggregability, is observed in migraine sufferers.
  • Calcium ions play a key role as second messengers in platelet activation.

Purpose of the Study:

  • To investigate the effect of nicardipine on platelet aggregation in migraine patients.
  • To determine if nicardipine modifies adenosine diphosphate (ADP)-induced platelet aggregation in migraine sufferers.

Main Methods:

  • Platelet-rich plasma (PRP) was obtained from control subjects and migraine sufferers.
  • Platelet aggregation was measured using arachidonic acid and adenosine diphosphate (ADP) as agonists.

Related Experiment Videos

  • Migraine sufferers received nicardipine treatment (20 mg three times daily for 2 months).

    • Main Results:

    • ADP-induced platelet aggregation was lower in untreated migraine sufferers compared to controls.
    • Nicardipine treatment significantly increased ADP-induced platelet aggregation in migraine sufferers.
    • Arachidonic acid-induced aggregation showed no significant difference between groups.

    Conclusions:

    • Nicardipine treatment appears to modulate platelet aggregation in migraine sufferers.
    • The findings suggest nicardipine may influence migraine pathophysiology or act directly on platelets.
    • Further research is needed to elucidate the precise mechanisms of nicardipine's action on platelet function in migraine.